JP2023500685A5 - - Google Patents
Info
- Publication number
- JP2023500685A5 JP2023500685A5 JP2022525779A JP2022525779A JP2023500685A5 JP 2023500685 A5 JP2023500685 A5 JP 2023500685A5 JP 2022525779 A JP2022525779 A JP 2022525779A JP 2022525779 A JP2022525779 A JP 2022525779A JP 2023500685 A5 JP2023500685 A5 JP 2023500685A5
- Authority
- JP
- Japan
- Prior art keywords
- alkoxy
- alkyl
- hydrogen
- pharmaceutical product
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930860P | 2019-11-05 | 2019-11-05 | |
| US62/930,860 | 2019-11-05 | ||
| PCT/IB2020/000912 WO2021090061A1 (en) | 2019-11-05 | 2020-11-04 | Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023500685A JP2023500685A (ja) | 2023-01-10 |
| JP2023500685A5 true JP2023500685A5 (https=) | 2023-11-13 |
| JP7502811B2 JP7502811B2 (ja) | 2024-06-19 |
Family
ID=75849803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525779A Active JP7502811B2 (ja) | 2019-11-05 | 2020-11-04 | Ｂｅｔブロモドメイン阻害物質およびナトリウム依存性グルコース輸送体２阻害物質の組み合わせで主要な心血管有害事象（ｍａｃｅ）を処置および／または予防する方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12551484B2 (https=) |
| EP (1) | EP4054584B1 (https=) |
| JP (1) | JP7502811B2 (https=) |
| KR (1) | KR102935008B1 (https=) |
| CN (1) | CN114650824A (https=) |
| AU (1) | AU2020377539B2 (https=) |
| BR (1) | BR112022008223A2 (https=) |
| CA (1) | CA3160147A1 (https=) |
| DK (1) | DK4054584T3 (https=) |
| ES (1) | ES3042146T3 (https=) |
| FI (1) | FI4054584T3 (https=) |
| HU (1) | HUE073043T2 (https=) |
| IL (1) | IL292696B1 (https=) |
| MX (1) | MX2022005029A (https=) |
| PL (1) | PL4054584T3 (https=) |
| PT (1) | PT4054584T (https=) |
| TW (1) | TWI867086B (https=) |
| WO (1) | WO2021090061A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114650824A (zh) | 2019-11-05 | 2022-06-21 | 雷斯韦洛吉克斯公司 | 用bet溴结构域抑制剂和钠依赖性葡萄糖转运蛋白2抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法 |
| US20230398137A1 (en) * | 2020-10-30 | 2023-12-14 | Resverlogix Corp. | Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| US20220370485A1 (en) * | 2021-01-14 | 2022-11-24 | Lexicon Pharmaceuticals, Inc. | Compounds and methods for treating or preventing cardiovascular diseases and conditions |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8410109B2 (en) | 2005-07-29 | 2013-04-02 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| SI2346837T1 (sl) | 2008-06-26 | 2015-05-29 | Resverlogix Corporation | Postopki pripravljanja kinazolinonskih derivatov |
| KR101913109B1 (ko) | 2009-03-18 | 2018-10-31 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| MX2011009852A (es) | 2009-03-27 | 2011-09-29 | Bristol Myers Squibb Co | Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv. |
| US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
| JP2012528170A (ja) | 2009-05-27 | 2012-11-12 | ブリストル−マイヤーズ スクイブ カンパニー | 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法 |
| CA2851996C (en) | 2011-11-01 | 2020-01-07 | Resverlogix Corp. | Pharmaceutical compositions for substituted quinazolinones |
| US20130281398A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| EP4678242A3 (en) | 2013-04-18 | 2026-03-18 | Boehringer Ingelheim International GmbH | Pharmaceutical composition, methods for treating and uses thereof |
| HK1219434A1 (zh) * | 2013-08-21 | 2017-04-07 | Resverlogix Corp. | 用於加速斑块消退的组合物和治疗方法 |
| AU2014310371A1 (en) | 2013-08-21 | 2016-03-10 | Resverlogix Corp. | Compositions and therapeutic methods for accelerated plaque regression |
| TW201625605A (zh) * | 2014-04-04 | 2016-07-16 | 賽諾菲公司 | 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類 |
| US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
| EP3355922A2 (en) * | 2015-10-02 | 2018-08-08 | Dana Farber Cancer Institute, Inc. | Combination therapy of bromodomain inhibitors and checkpoint blockade |
| EP3553058A1 (en) | 2016-12-09 | 2019-10-16 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of bromodomain protein inhibitor drug, preparation method and use thereof |
| US11419883B2 (en) | 2017-05-05 | 2022-08-23 | The Regents Of The University Of California | Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes |
| CN114650824A (zh) | 2019-11-05 | 2022-06-21 | 雷斯韦洛吉克斯公司 | 用bet溴结构域抑制剂和钠依赖性葡萄糖转运蛋白2抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法 |
| JP7763761B2 (ja) | 2020-01-08 | 2025-11-04 | レスバーロジックス コーポレイション | Ｂｅｔブロモドメイン阻害剤およびジペプチジルペプチダーゼ４阻害剤の組合せによる主要有害心血管イベント（ｍａｃｅ）の治療方法および／または予防方法 |
| US20230398137A1 (en) * | 2020-10-30 | 2023-12-14 | Resverlogix Corp. | Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| CA3197706A1 (en) | 2020-10-30 | 2022-05-05 | Resverlogix Corp. | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
-
2020
- 2020-11-04 CN CN202080076646.1A patent/CN114650824A/zh active Pending
- 2020-11-04 HU HUE20884269A patent/HUE073043T2/hu unknown
- 2020-11-04 WO PCT/IB2020/000912 patent/WO2021090061A1/en not_active Ceased
- 2020-11-04 BR BR112022008223A patent/BR112022008223A2/pt unknown
- 2020-11-04 PT PT208842690T patent/PT4054584T/pt unknown
- 2020-11-04 EP EP20884269.0A patent/EP4054584B1/en active Active
- 2020-11-04 FI FIEP20884269.0T patent/FI4054584T3/fi active
- 2020-11-04 AU AU2020377539A patent/AU2020377539B2/en active Active
- 2020-11-04 PL PL20884269.0T patent/PL4054584T3/pl unknown
- 2020-11-04 US US17/774,657 patent/US12551484B2/en active Active
- 2020-11-04 DK DK20884269.0T patent/DK4054584T3/da active
- 2020-11-04 KR KR1020227019038A patent/KR102935008B1/ko active Active
- 2020-11-04 JP JP2022525779A patent/JP7502811B2/ja active Active
- 2020-11-04 CA CA3160147A patent/CA3160147A1/en active Pending
- 2020-11-04 TW TW109138504A patent/TWI867086B/zh active
- 2020-11-04 ES ES20884269T patent/ES3042146T3/es active Active
- 2020-11-04 IL IL292696A patent/IL292696B1/en unknown
- 2020-11-04 MX MX2022005029A patent/MX2022005029A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11026900B2 (en) | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | |
| US6432950B1 (en) | Method for inhibiting neoplastic cells and related conditions by exposure to benzothienopyrimidine derivatives | |
| JP2023500685A5 (https=) | ||
| JP7697885B2 (ja) | 化合物の製剤およびそれらの使用 | |
| US9814724B2 (en) | Antitumor effect potentiator and antitumor agent | |
| RU2008133654A (ru) | Способ и лекарственное средство для лечения тяжелой сердечной недостаточности | |
| CN101107001A (zh) | 配合有α,α,α-三氟胸苷和胸苷磷酸化酶抑制剂的抗癌剂 | |
| IL292696A (en) | Methods for the treatment and/or prevention of severe harmful cardiovascular events with a combination of a bromodomain bet inhibitor and a sodium-dependent glucose transporter 2 inhibitor | |
| JP2023509186A5 (https=) | ||
| WO2020045461A1 (ja) | ピラゾロ［３，４－ｄ］ピリミジン化合物を有効成分とする治療剤 | |
| JP2023547475A5 (https=) | ||
| JP2023549703A5 (https=) | ||
| JP5409613B2 (ja) | 抗腫瘍剤、キット及び癌治療方法 | |
| JP3450399B2 (ja) | 血管新生阻害剤 | |
| JPS6231689B2 (https=) | ||
| HK1127546A (en) | Antitumor effect potentiator and antitumor agent | |
| KR20070026443A (ko) | 허혈성 순환기 질환의 예방 및/또는 치료를 위한 약제 |